Ipsen Investor Relations Material

Ipsen S.A. provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders and rare diseases. The company's products include Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell ad second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure and GH deficiency in adults; Increlex for growth failure in children and adolescents.